TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34922567
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure plus rescue medication (RM)
Study: 32764634
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic lozenges containing Streptococcus salivarius M18
Study: 33207935
Drug: Prazosin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (16 mg/day, with a 2-week titration)
Study: 35148195
Drug: YES-10 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YES-10 (200 mg, 2 capsules daily for 4 weeks)
Study: 35148195
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules daily for 4 weeks)
Study: 32009286
Drug: Newer glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer glucose-lowering medications (sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists)
Study: 35970013
Drug: Multiagent induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent induction chemotherapy (ICT; nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX) for 16 weeks
Study: 35970013
Drug: Multiagent induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent induction chemotherapy (ICT) with robust CA 19-9 response (decrease to ≤50 U/ml)
Study: 35970013
Drug: CA 19-9
Normalized name: CA-19-9 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 19-9 decrease to ≤61 U/ml as optimal cut-off
Study: 38251533
Drug: Riociguat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (up to 2.5 mg three times daily)
Study: 33779938
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg once daily
Study: 34710363
Drug: Supervised primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised primaquine treatment (0.5 mg/kg per day for 14 days, supervised on alternate days)
Study: 34710363
Drug: Unsupervised primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised primaquine treatment (0.5 mg/kg per day for 14 days, unsupervised)
Study: 34710363
Drug: Supervised primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised primaquine treatment
Study: 34710363
Drug: Unsupervised primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised primaquine treatment
Study: 36196180
Drug: Low-dose hydroxyurea
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydroxyurea
Study: 36196180
Drug: Moderate-dose hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose hydroxyurea
Study: 36196180
Drug: State-supported stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-supported stroke screening service and treatment
Study: 36053298
Drug: Oral OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OXT (24IU)
Study: 33356529
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg/day) plus androgen deprivation therapy
Study: 37945297
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose
Study: 33361029
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg every 12 hours)
Study: 33361029
Drug: Prednisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (20 mg once daily for 2 weeks)
Study: 32514820
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g or 30 g 10% trehalose solution administered weekly via IV
Study: 37878483
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1 g/day)
Study: 35172587
Drug: Xevinapant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xevinapant monotherapy
Study: 34226496
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications associated with weight gain
Study: 34226496
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications with high risk of weight gain
Study: 32618247
Drug: Dihydroartemisinin-Piperaquine (DHAP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-Piperaquine (DHAP) administered in four rounds of mass drug administration (MDA)
Study: 32618247
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care without any mass treatment
Study: 34405423
Drug: MultiPole Pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiPole Pacing (MPP) therapy
Study: 32215583
Drug: SRT plus
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) for 2 years
Study: 36329722
Drug: Aframomum melegueta
Normalized name: Aframomum angustifolium seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aframomum melegueta seed extract (AfperFit) 250 mg, twice daily for 12 weeks
Study: 33037808
Drug: Xylitol–malic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol–malic acid tablets (as a supplement to omeprazole 40 mg/day)
Study: 35118156
Drug: Autologous adipose-derived
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose-derived stromal vascular fractions (SVF) injections
Study: 34332547
Drug: Cerebral oxygenation
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral oxygenation monitoring treatment
Study: 34332547
Drug: Monitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring and treatment as usual
Study: 33876259
Drug: Ibuprofen before
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen before exercise (IP)
Study: 33876259
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before and ibuprofen after exercise (PI)
Study: 32545223
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with toluidine blue O and LED light, applied at baseline and 3-months in addition to non-surgical periodontal treatment
Study: 32571859
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise programme (12-week tailored programme with weekly telephone calls for exercise progression)
Study: 34127645
Drug: Jackfruit365™ green
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jackfruit365™ green jackfruit flour 30 g/day (Group A)
Study: 33451962
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (20 mg bolus followed by 5 μg/kg/min infusion)
Study: 33451962
Drug: Narcotic-only control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic-only control (100 μg fentanyl with additional fentanyl and 0.3 mg hydromorphone)
Study: 32160948
Drug: RV3-BB rotavirus
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB rotavirus vaccine (neonatal schedule, first dose at 0-5 days of age)
Study: 32160948
Drug: RV3-BB rotavirus
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB rotavirus vaccine (infant schedule, first dose at 8 weeks of age)
Study: 32823413
Drug: Anti-VEGF monotherapy
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF monotherapy
Study: 37716893
Drug: Treatment-as-usual (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control condition)
Study: 33735670
Drug: Inhaled levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levosimendan (LS)
Study: 33735670
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan (LS)
Study: 32569102
Drug: Daily 30-minute
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily 30-minute massage for 7 consecutive days
Study: 32569102
Drug: Daily 30-minute
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily 30-minute restriction of non-essential caregiving (Quiet Time) for 7 consecutive days
Study: 34973853
Drug: burn+glutamine (B+G)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: burn+glutamine (B+G)
Study: 34187394
Drug: Nifedipine/indomethacin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine/indomethacin combination therapy
Study: 33527395
Drug: Eperisone 50
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone 50 mg (Murex®)
Study: 616886746
Drug: Chinese medicine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine-based nursing care
Study: 34306274
Drug: Multidimensional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional treatment (MT) group, n = 30
Study: 34306274
Drug: Unimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unimodal treatment (UT) group, n = 30
Study: 35352373
Drug: Gluten (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (10 g in two granola bars for 7 days)
Study: 32244279
Drug: Multivitamins (containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins (containing 50 µg vitamin B12)
Study: 35763357
Drug: Levosimendan 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.1 mcg/kg/min from anesthetic induction
Study: 35763357
Drug: Milrinone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone 0.5 mcg/kg/min (control)
Study: 36443540
Drug: Non-chemotherapy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-chemotherapy
Study: 32710888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with normal daily habits
Study: 34649590
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly sessions of virtually delivered qualified exercise professional (QEP) support
Study: 34649590
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly sessions of virtually delivered QEP support
Study: 32291982
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 1.0 g TXA before operation (Group B)
Study: 32291982
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 1.0 g TXA before operation combined with local use of TXA cocktail during operation (Group C)
Study: 32291982
Drug: No TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TXA administered (Group A)
Study: 33653410
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation training (eight 90-min sessions, one session weekly)
Study: 34670026
Drug: Deep Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Brain Stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS)
Study: 32591421
Drug: Fructose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (20 g) intake 30 minutes prior to exercise
Study: 35522900
Drug: ATx201 OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATx201 OINTMENT 2%
Study: 33393175
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection
Study: 38923910
Drug: Chemotherapy (Chemo)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Chemo)
Study: 33317621
Drug: MSI-195 (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSI-195 (400, 800, and 1600 mg)
Study: 32506228
Drug: S. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. salivarius K12 lozenge
Study: 34272087
Drug: Systemic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapies
Study: 34514495
Drug: Free diet
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free diet and single donor standard faecal transplantation (FT) by colonoscopy on Day 1 and rectal enemas on Days 2 and 14 without dietary conditioning of the donor.
Study: 33795297
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide injections (40 ?g/week)
Study: 39555822
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation
Study: 34711071
Drug: Weekly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow-up meetings
Study: 33512387
Drug: OMT +
Normalized name: Omtryg
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT + medication group
Study: 32862437
Drug: Dexmedetomidine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (3.5 µg/kg followed by 7 µg/kg/h) administered before ischaemia (preconditioning)
Study: 32862437
Drug: Dexmedetomidine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (3.5 µg/kg followed by 7 µg/kg/h) administered after beginning ischaemia (post-conditioning)
Study: 35742717
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioral therapy
Study: 34400865
Drug: Community pharmacy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacy-based medication therapy management programme
Study: 35562420
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation among patients using calcium channel blockers
Study: 33746216
Drug: PUFAs supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFAs supplementation (1000 mg daily)
Study: 33493448
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin sodium 25,000 IU in 5 mL, administered every 6 hours for 10 days via nebuliser
Study: 33493448
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin sodium 25,000 IU in 5 mL
Study: 34148172
Drug: Oral Neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Neomycin and Bacitracin (OIVA group)
Study: 34148172
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (IVA group)
Study: 34148172
Drug: OIVA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIVA with mechanical bowel preparation (MBP)
Study: 34148172
Drug: IVA with
Normalized name: Floriva with 0.25mg Fluoride and Vitamin D Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVA with mechanical bowel preparation (MBP)
Study: 34411060
Drug: Droperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (20 ?g/kg)
Study: 33735275
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (high frequency) - multiple component incentive for home testing, attendance of weekly telephone education classes and absolute HbA1c reduction
Study: 35233748
Drug: Glycyrrhizin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (60 mg) and Boswellic acids (200 mg) twice daily for 14 days
Study: 32804205
Drug: Erythropoietin 1000
Normalized name: ERYTHROPOIETIN 10000 UNT/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 1000 U/kg every 48 hours for 6 doses, followed by 400 U/kg 3 times a week through postmenstrual age of 32 weeks.
Study: 32804205
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham injections).
Study: 34518263
Drug: Micronised purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised purified flavonoid fraction (MPFF, Venixxa) 1000 mg orally for 6 months
Study: 35421233
Drug: RRB (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRB (125 g fresh equivalents) daily
Study: 35421233
Drug: RRB +
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RRB + FOS (8g) daily
Study: 34918028
Drug: EFV1 (efavirenz
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV1 (efavirenz with TB treatment containing rifapentine 1200mg, isoniazid, pyrazinamide, and either ethambutol or moxifloxacin)
Study: 34918028
Drug: EFV2 (newly
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV2 (newly initiating efavirenz with TB treatment containing rifapentine 1200mg, isoniazid, pyrazinamide, and either ethambutol or moxifloxacin)
Study: 32767506
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei TH14 (105 cfu/kg FM) + cellulase (10,000 unit/kg FM) + molasses (50 g/kg FM)
Study: 32767506
Drug: Cellulase (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulase (10,000 unit/kg FM) + molasses (50 g/kg FM)
Study: 32767506
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei TH14 (105 cfu/kg FM) + molasses (50 g/kg FM)
Study: 36036095
Drug: Clustered missed
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clustered missed doses
Study: 36036095
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment days missed
Study: 34137446
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of fibrin patch
Study: 35799553
Drug: Triidothyronine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triidothyronine 1 mic/kg 10 doses 8th hourly given orally postoperatively
Study: 35946332
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine and subcutaneous morphine (rapid titration)
Study: 35946332
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (control)
Study: 36737698
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg triamcinolone acetonide
Study: 35179323
Drug: Darolutamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darolutamide (600 mg twice daily)
Study: 34692441
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily for 10 days
Study: 34060988
Drug: Cuyuxunxi (CYXX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuyuxunxi (CYXX) prescription
Study: 34601551
Drug: Medium-dose spice
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose spice diet (MSD) 3.285 g · d‐1 · 2100 kcal‐1 for 4 weeks
Study: 34601551
Drug: High-dose spice
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spice diet (HSD) 6.571 g · d‐1 · 2100 kcal‐1 for 4 weeks
Study: 32060566
Drug: 50 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/day VK2
Study: 32060566
Drug: 90 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 µg/day VK2
Study: 32060566
Drug: Co-supplementation with
Normalized name: zinc bandage with supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-supplementation with calcium (500 mg/day) and vitamin D3 (10 µg/day)
Study: 33040841
Drug: Trazodone/gabapentin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone/gabapentin combination (2.5/25, 10/100, 30/300)
Study: 33040841
Drug: Trazodone/gabapentin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone/gabapentin combination (10/100)
Study: 34914338
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 250 mg daily (AA250 arm)
Study: 34914338
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg daily (AA500 arm)
Study: 34996918
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml DW5
Study: 33105146
Drug: Liraglutide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (titrated to maximum tolerable dose up to 1.8 mg)
Study: 35599918
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (4000 IU weekly)
Study: 33522909
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefazolin
Study: 33289350
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg FT-4101
Study: 35565738
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg gluten
Study: 35565738
Drug: Gluten administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten administration (all doses)
Study: 34529686
Drug: No intervention/treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention/treatment as usual
Study: 35392153
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 µg/ml)
Study: 35392153
Drug: Sufentanyl (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanyl (0.4 µg/ml)
Study: 34978861
Drug: Quadpill containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadpill containing quarter doses of 4 blood pressure drugs
Study: 34978861
Drug: Standard-dose monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose monotherapy
Study: 35346485
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 to 100 mg)
Study: 35346485
Drug: Standard hypotensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hypotensive treatment (ST)